NRX Pharmaceuticals Inc (NRXP)
3.07
+0.07
(+2.33%)
USD |
NASDAQ |
Apr 23, 16:00
3.05
-0.02
(-0.65%)
After-Hours: 20:00
NRX Pharmaceuticals Cash from Operations (TTM): -21.66M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -21.66M |
| September 30, 2023 | -26.78M |
| June 30, 2023 | -28.48M |
| March 31, 2023 | -35.46M |
| December 31, 2022 | -39.76M |
| Date | Value |
|---|---|
| September 30, 2022 | -42.72M |
| June 30, 2022 | -48.46M |
| March 31, 2022 | -45.07M |
| December 31, 2021 | -37.70M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-48.46M
Minimum
Jun 2022
-21.66M
Maximum
Dec 2023
-36.23M
Average
-37.70M
Median
Dec 2021
Cash from Operations (TTM) Benchmarks
| Achieve Life Sciences Inc | -24.48M |
| Dare Bioscience Inc | -38.86M |
| Zevra Therapeutics Inc | -33.54M |
| Kodiak Sciences Inc | -154.18M |
| INmune Bio Inc | -11.98M |